RHB-105

DRUG2 trials

Sponsors

RedHill Biopharma Limited

Conditions

DyspepsiaHelicobacter Pylori Infection

Phase 3

ERADICATE Hp - Treating Helicobacter Pylori With RHB-105

CompletedNCT01980095

RedHill Biopharma LimitedDyspepsia, Helicobacter Pylori Infection

Start: 2013-11-30End: 2015-08-31Updated: 2019-09-24

ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator

CompletedNCT03198507

RedHill Biopharma LimitedDyspepsia, Helicobacter Pylori Infection

Start: 2017-06-18End: 2018-12-13Updated: 2020-03-16

Related Papers

S1597 Modeling Gastric Luminal Rifabutin Concentrations: RHB-105 (Rifabutin 50 mg Q8H) Provides More Favorable Exposure for Helicobacter pylori Eradication Than Generic Rifabutin 150 mg BID or 300 mg QD

The American Journal of Gastroenterology2022-10-01

Pitfalls of Physician-Directed Treatment of Helicobacter pylori: Results from Two Phase 3 Clinical Trials and Real-World Prescribing Data.

2021-12-047 citations

S1451 Pitfalls of Physician-Directed Treatment of H. pylori Infection: Results From Two Phase 3 Clinical Trials and Real-World Prescribing Data

The American Journal of Gastroenterology2021-10-01

S1417 RHB-105 Q8H Rifabutin Dosing Provides Favorable Exposure for Helicobacter pylori Eradication

The American Journal of Gastroenterology2021-10-01

<i>Helicobacter pylori</i> eradication by low‐dose rifabutin triple therapy (RHB‐105) is unaffected by high body mass index

GastroHep2021-09-281 citations

S1342 Efficacy of H. pylori Eradication by Low-Dose Rifabutin Triple Therapy (RHB-105) Is Unaffected by BMI: Post-hoc Analysis From Two Phase 3 Trials

The American Journal of Gastroenterology2020-10-01

Rifabutin-Based Triple Therapy (RHB-105) for <i>Helicobacter pylori</i> Eradication: A Double-Blind, Randomized, Controlled Trial.

2020-05-0559 citations

1200 Rifabutin (RHB-105) Based Triple Therapy for Helicobacter pylori (HP) Infection Eradication: Results of Pivotal Phase 3 Multi-Center Study (ERADICATE Hp2)

The American Journal of Gastroenterology2019-10-01